VHCP Management II as of March 31, 2017
Portfolio Holdings for VHCP Management II
VHCP Management II holds 20 positions in its portfolio as reported in the March 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Avexis | 32.2 | $79M | 1.0M | 76.03 | |
| BioCryst Pharmaceuticals (BCRX) | 20.9 | $51M | 6.1M | 8.40 | |
| Ascendis Pharma A S (ASND) | 9.3 | $23M | 812k | 28.00 | |
| Dbv Technologies (DBVTF) | 7.6 | $19M | 374k | 50.01 | |
| Edge Therapeutics | 7.2 | $18M | 1.9M | 9.11 | |
| Ra Pharmaceuticals | 6.3 | $15M | 725k | 21.29 | |
| Audentes Therapeutics | 3.2 | $7.8M | 459k | 17.04 | |
| Axovant Sciences | 2.6 | $6.4M | 430k | 14.94 | |
| Cytomx Therapeutics (CTMX) | 2.0 | $5.0M | 289k | 17.27 | |
| Acceleron Pharma | 1.7 | $4.2M | 157k | 26.47 | |
| Akari Therapeutics | 1.7 | $4.1M | 370k | 11.07 | |
| ARCA biopharma | 1.1 | $2.8M | 1.1M | 2.55 | |
| Coherus Biosciences (CHRS) | 0.8 | $2.0M | 95k | 21.15 | |
| D Stemline Therapeutics | 0.8 | $2.0M | 228k | 8.55 | |
| Lipocine | 0.7 | $1.6M | 420k | 3.90 | |
| Kalvista Pharmaceuticals (KALV) | 0.7 | $1.6M | 222k | 7.38 | |
| Ocera Therapeutics | 0.7 | $1.6M | 1.2M | 1.31 | |
| Adverum Biotechnologies | 0.3 | $756k | 280k | 2.70 | |
| Alcobra | 0.1 | $211k | 185k | 1.14 | |
| Sierra Oncology | 0.1 | $200k | 131k | 1.53 |
